|
1
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Acunzo J, Baylot V, So A and Rocchi P:
TCTP as therapeutic target in cancers. Cancer Treat Rev.
40:760–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amson R, Pece S, Marine JC, Di Fiore PP
and Telerman A: TPT1/TCTP-regulated pathways in phenotypic
reprogramming. Trends Cell Biol. 23:37–46. 2013. View Article : Google Scholar
|
|
4
|
Chan TH, Chen L and Guan XY: Role of
translationally controlled tumor protein in cancer progression.
Biochem Res Int. 2012:3693842012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Amson R, Pece S, Lespagnol A, Vyas R,
Mazzarol G, Tosoni D, Colaluca I, Viale G, Rodrigues-Ferreira S,
Wynendaele J, et al: Reciprocal repression between P53 and TCTP.
Nat Med. 18:91–99. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan TH, Chen L, Liu M, Hu L, Zheng BJ,
Poon VK, Huang P, Yuan YF, Huang JD, Yang J, et al: Translationally
controlled tumor protein induces mitotic defects and chromosome
missegregation in hepatocellular carcinoma development. Hepatology.
55:491–505. 2012. View Article : Google Scholar
|
|
7
|
Xiao B, Chen D, Luo S, Hao W, Jing F, Liu
T, Wang S, Geng Y, Li L, Xu W, et al: Extracellular translationally
controlled tumor protein promotes colorectal cancer invasion and
metastasis through Cdc42/JNK/MMP9 signaling. Oncotarget.
7:50057–50073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma Q, Geng Y, Xu W, Wu Y, He F, Shu W,
Huang M, Du H and Li M: The role of translationally controlled
tumor protein in tumor growth and metastasis of colon
adenocarcinoma cells. J Proteome Res. 9:40–49. 2010. View Article : Google Scholar
|
|
9
|
Ueda M, Takahashi Y, Shinden Y, Sakimura
S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, et
al: Prognostic significance of high mobility group box 1 (HMGB1)
expression in patients with colorectal cancer. Anticancer Res.
34:5357–5362. 2014.PubMed/NCBI
|
|
10
|
Zhang Z, Wang M, Zhou L, Feng X, Cheng J,
Yu Y, Gong Y, Zhu Y, Li C, Tian L, et al: Increased HMGB1 and
cleaved caspase-3 stimulate the proliferation of tumor cells and
are correlated with the poor prognosis in colorectal cancer. J Exp
Clin Cancer Res. 34:512015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Süren D, Yıldırım M, Demirpençe Ö, Kaya V,
Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high
mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit.
20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Beijnum JR, Buurman WA and Griffioen
AW: Convergence and amplification of toll-like receptor (TLR) and
receptor for advanced glycation end products (RAGE) signaling
pathways via high mobility group B1 (HMGB1). Angiogenesis.
11:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dumitriu IE, Baruah P, Valentinis B, Voll
RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA and
Rovere-Querini P: Release of high mobility group box 1 by dendritic
cells controls T cell activation via the receptor for advanced
glycation end products. J Immunol. 174:7506–7515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS,
Ahn YH, Yoo JS, Paik YK and Kim H: Non-histone nuclear factor HMGB1
is phosphorylated and secreted in colon cancers. Lab Invest.
89:948–959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee W, Ku SK, Bae JW and Bae JS:
Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory
responses in both cellular and animal models. Food Chem Toxicol.
50:1826–1833. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sims GP, Rowe DC, Rietdijk ST, Herbst R
and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev
Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nogueira-Machado JA and de Oliveira Volpe
CM: HMGB-1 as a target for inflammation controlling. Recent Pat
Endocr Metab Immune Drug Discov. 6:201–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nogueira-Machado JA, Volpe CM, Veloso CA
and Chaves MM: HMGB1, TLR and RAGE: A functional tripod that leads
to diabetic inflammation. Expert Opin Ther Targets. 15:1023–1035.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, He J, Zhong D, Li J and Liang H:
High-mobility group box 1 protein activating nuclear factor-κB to
upregulate vascular endothelial growth factor C is involved in
lymphangiogenesis and lymphatic node metastasis in colon cancer. J
Int Med Res. 43:494–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Liu Z, Wang L and Zhang X:
NF-kappaB signaling pathway, inflammation and colorectal cancer.
Cell Mol Immunol. 6:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raina K, Agarwal C and Agarwal R: Effect
of silibinin in human colorectal cancer cells: Targeting the
activation of NF-κB signaling. Mol Carcinog. 52:195–206. 2013.
View Article : Google Scholar
|
|
22
|
Chang MS, Kim DH, Roh JK, Middeldorp JM,
Kim YS, Kim S, Han S, Kim CW, Lee BL, Kim WH, et al: Epstein-Barr
virus-encoded BARF-1 promotes proliferation of gastric carcinoma
cells through regulation of NF-κB. J Virol. 87:10515–10523. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shafiu Kamba A and Zakaria ZA: Osteoblasts
growth behaviour on bio-based calcium carbonate aragonite
nanocrystal. BioMed Res Int. 2014:2150972014. View Article : Google Scholar :
|
|
24
|
Bommer UA, Vine KL, Puri P, Engel M,
Belfiore L, Fildes K, Batterham M, Lochhead A and Aghmesheh M:
Translationally controlled tumour protein TCTP is induced early in
human colorectal tumours and contributes to the resistance of
HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun
Signal. 15:92017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Yu J, Li M, Zhu H, Sun X and Kong
L: The association of HMGB1 expression with clinicopathological
significance and prognosis in Asian patients with colorectal
carcinoma: A meta-analysis and literature review. OncoTargets Ther.
9:4901–4911. 2016. View Article : Google Scholar
|
|
26
|
Lee H, Song M, Shin N, Shin CH, Min BS,
Kim HS, Yoo JS and Kim H: Diagnostic significance of serum HMGB1 in
colorectal carcinomas. PLoS One. 7:e343182012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo Y, Chihara Y, Fujimoto K, Sasahira T,
Kuwada M, Fujiwara R, Fujii K, Ohmori H and Kuniyasu H: High
mobility group box 1 released from necrotic cells enhances regrowth
and metastasis of cancer cells that have survived chemotherapy. Eur
J Cancer. 49:741–751. 2013. View Article : Google Scholar
|
|
28
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen RC, Yi PP, Zhou RR, Xiao MF, Huang
ZB, Tang DL, Huang Y and Fan XG: The role of HMGB1-RAGE axis in
migration and invasion of hepatocellular carcinoma cell lines. Mol
Cell Biochem. 390:271–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Völp K, Brezniceanu ML, Bösser S, Brabletz
T, Kirchner T, Göttel D, Joos S and Zörnig M: Increased expression
of high mobility group box 1 (HMGB1) is associated with an elevated
level of the antiapoptotic c-IAP2 protein in human colon
carcinomas. Gut. 55:234–242. 2006. View Article : Google Scholar
|
|
31
|
Sharma S, Evans A and Hemers E:
Mesenchymal-epithelial signalling in tumour microenvironment: Role
of high-mobility group Box 1. Cell Tissue Res. 365:357–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han M, Song Y and Zhang X: Quercetin
suppresses the migration and invasion in human colon cancer Caco-2
cells through regulating toll-like receptor 4/nuclear factor-kappa
B pathway. Pharmacogn Mag. 12(Suppl 2): S237–S244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yesudhas D, Gosu V, Anwar MA and Choi S:
Multiple roles of toll-like receptor 4 in colorectal cancer. Front
Immunol. 5:3342014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng R, Wu H, Ran H, Kong X, Hu L, Wang X
and Su Q: Glucose-derived AGEs promote migration and invasion of
colorectal cancer by up-regulating Sp1 expression. Biochim Biophys
Acta. 1861:1065–1074. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dahlmann M, Okhrimenko A, Marcinkowski P,
Osterland M, Herrmann P, Smith J, Heizmann CW, Schlag PM and Stein
U: RAGE mediates S100A4-induced cell motility via MAPK/ERK and
hypoxia signaling and is a prognostic biomarker for human
colorectal cancer metastasis. Oncotarget. 5:3220–3233. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee H and Lee K: Dimerized translationally
controlled tumor protein increases interleukin-8 expression through
MAPK and NF-κB pathways in a human bronchial epithelial cell line.
Cell Biosci. 8:132018. View Article : Google Scholar
|
|
37
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vaiopoulos AG, Athanasoula KC and
Papavassiliou AG: NF-κB in colorectal cancer. J Mol Med (Berl).
91:1029–1037. 2013. View Article : Google Scholar
|
|
40
|
Chen S, Chen W, Zhang X, Lin S and Chen Z:
Overexpression of KiSS-1 reduces colorectal cancer cell invasion by
downregulating MMP-9 via blocking PI3K/Akt/NF-κB signal pathway.
Int J Oncol. 48:1391–1398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qin M and Liu S, Li A, Xu C, Tan L, Huang
J and Liu S: NIK- and IKKβ-binding protein promotes colon cancer
metastasis by activating the classical NF-κB pathway and MMPs.
Tumour Biol. 37:5979–5990. 2016. View Article : Google Scholar
|
|
42
|
Zhu L, Li X, Chen Y, Fang J and Ge Z:
High-mobility group box 1: A novel inducer of the
epithelial-mesenchymal transition in colorectal carcinoma. Cancer
Lett. 357:527–534. 2015. View Article : Google Scholar
|
|
43
|
Ma J, Gao Q, Zeng S and Shen H: Knockdown
of NDRG1 promote epithelial-mesenchymal transition of colorectal
cancer via NF-κB signaling. J Surg Oncol. 114:520–527. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yan Z, Yin H, Wang R, Wu D, Sun W, Liu B
and Su Q: Overexpression of integrin-linked kinase (ILK) promotes
migration and invasion of colorectal cancer cells by inducing
epithelial-mesenchymal transition via NF-κB signaling. Acta
Histochem. 116:527–533. 2014. View Article : Google Scholar
|
|
45
|
Bae SY, Kim HJ, Lee KJ and Lee K:
Translationally controlled tumor protein induces epithelial to
mesenchymal transition and promotes cell migration, invasion and
metastasis. Sci Rep. 5:80612015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Richard SA, Jiang Y, Xiang LH, Zhou S,
Wang J, Su Z and Xu H: Post-translational modifications of high
mobility group box 1 and cancer. Am J Transl Res. 9:5181–5196.
2017.
|
|
47
|
Huebener P, Pradere JP, Hernandez C, Gwak
GY, Caviglia JM, Mu X, Loike JD, Jenkins RE, Antoine DJ and Schwabe
RF: The HMGB1/RAGE axis triggers neutrophil-mediated injury
amplification following necrosis. J Clin Invest. 125:539–550. 2015.
View Article : Google Scholar : PubMed/NCBI
|
